Corvus Pharmaceuticals, Inc.
CRVS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $611 | $311 | $229 | $366 |
| - Cash | $3 | $15 | $5 | $9 |
| + Debt | $1 | $1 | $1 | $1 |
| Enterprise Value | $609 | $297 | $226 | $358 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$10 | -$10 | -$10 | -$8 |
| % Margin | – | – | – | – |
| Net Income | -$10 | -$8 | $15 | -$12 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.12 | -0.1 | -0.13 | -0.18 |
| % Growth | -20% | 23.1% | 27.8% | – |
| Operating Cash Flow | -$10 | -$6 | -$8 | -$8 |
| Capital Expenditures | $0 | -$0 | -$0 | $0 |
| Free Cash Flow | -$10 | -$6 | -$8 | -$8 |